Breaking News Instant updates and real-time market news.

$NYE

NYSE Market Internals

/

+

14:16
02/03/23
02/03
14:16
02/03/23
14:16

NYSE market internals summary

Volume is above average for this time of day. Breadth is mixed with issues and volume bearish while new highs to new lows are bullish (positive divergence). Advancing Issues: 811 / Declining Issues: 2223 -- for a ratio of 0.4 to 1. Advancing Volume: 847,947,000 / Declining Volume: 1,936,514,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 112 / New 52-Week Lows: 9.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Puma presents biomarker findings from Phase II study in HR+, TN breast cancer » 09:08
06/04/23
06/04
09:08
06/04/23
09:08
PBYI

Puma Biotechnology

$3.56 /

+0.115 (+3.34%)

Puma Biotechnology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 09:08

Get Free Trial

ShowHide Related Items >><<
PBYI Puma Biotechnology
$3.56 /

+0.115 (+3.34%)

PBYI Puma Biotechnology
$3.56 /

+0.115 (+3.34%)

08/05/22 H.C. Wainwright
Puma Biotechnology price target lowered to $8 from $12 at H.C. Wainwright
PBYI Puma Biotechnology
$3.56 /

+0.115 (+3.34%)

Hot Stocks
Amgen presents new LUMAKRAS CodeBreaK 200 CNS data at ASCO » 08:48
06/04/23
06/04
08:48
06/04/23
08:48
AMGN

Amgen

$218.03 /

+3.76 (+1.75%)

Amgen announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:48

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$218.03 /

+3.76 (+1.75%)

AMGN Amgen
$218.03 /

+3.76 (+1.75%)

06/01/23 Wells Fargo
Wells says Coherus' Humira biosimilar pricing 'actually good news' for AbbVie
05/16/23 Stifel
Seagen likely to stay 'distanced' from deal price after FTC action, says Stifel
05/16/23 Jefferies
Jefferies thinks Amgen-Horizon deal still gets done after 'speed bump'
05/03/23 Mizuho
Amgen price target raised to $214 from $208 at Mizuho
AMGN Amgen
$218.03 /

+3.76 (+1.75%)

AMGN Amgen
$218.03 /

+3.76 (+1.75%)

AMGN Amgen
$218.03 /

+3.76 (+1.75%)

AMGN Amgen
$218.03 /

+3.76 (+1.75%)

Hot Stocks
Bristol-Myers presents follow-up results from Phase 3 CheckMate -9LA trial » 08:45
06/04/23
06/04
08:45
06/04/23
08:45
BMY

Bristol-Myers

$65.66 /

+0.98 (+1.52%)

Bristol-Myers Squibb…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:45

Get Free Trial

ShowHide Related Items >><<
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

05/01/23 Barclays
Bristol-Myers price target lowered to $65 from $66 at Barclays
04/28/23 Credit Suisse
Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
04/21/23 BofA
Bristol-Myers price target raised to $85 from $82 at BofA
04/20/23 H.C. Wainwright
Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

Hot Stocks
ImmunoGen presents results Phase 3 confirmatory MIRASOL trial » 08:41
06/04/23
06/04
08:41
06/04/23
08:41
IMGN

ImmunoGen

$14.36 /

+0.195 (+1.38%)

ImmunoGen announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:41

Get Free Trial

ShowHide Related Items >><<
IMGN ImmunoGen
$14.36 /

+0.195 (+1.38%)

IMGN ImmunoGen
$14.36 /

+0.195 (+1.38%)

05/03/23 Piper Sandler
ImmunoGen upgraded to Overweight at Piper after 'overwhelmingly positive' data
05/03/23 H.C. Wainwright
H.C. Wainwright reiterates Buy on ImmunoGen following MIRASOL 'homerun'
05/03/23 Piper Sandler
ImmunoGen upgraded to Overweight from Neutral at Piper Sandler
05/03/23 Guggenheim
ImmunoGen's MIRASOL trial results represent best-case scenario, says Guggenheim
IMGN ImmunoGen
$14.36 /

+0.195 (+1.38%)

  • 05
    May
IMGN ImmunoGen
$14.36 /

+0.195 (+1.38%)

IMGN ImmunoGen
$14.36 /

+0.195 (+1.38%)

Hot Stocks
Summit presents data for investigational bispecific antibody ivonescimab » 08:28
06/04/23
06/04
08:28
06/04/23
08:28
SMMT

Summit Therapeutics

$1.81 /

+0.09 (+5.25%)

Summit Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:28

Get Free Trial

ShowHide Related Items >><<
SMMT Summit Therapeutics
$1.81 /

+0.09 (+5.25%)

SMMT Summit Therapeutics
$1.81 /

+0.09 (+5.25%)

SMMT Summit Therapeutics
$1.81 /

+0.09 (+5.25%)

Hot Stocks
AstraZeneca says TAGRISSO achieved 'unprecedent' survival in EGFRm » 08:24
06/04/23
06/04
08:24
06/04/23
08:24
AZN

AstraZeneca

$72.57 /

-0.27 (-0.37%)

AstraZeneca says…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:24

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

05/26/23 Argus
AstraZeneca price target lowered to $80 from $85 at Argus
05/09/23 Berenberg
AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
04/28/23 JPMorgan
AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
04/13/23 Argus
AstraZeneca price target raised to $85 from $75 at Argus
AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

AZN AstraZeneca
$72.57 /

-0.27 (-0.37%)

Hot Stocks
G1 Therapeutics presents data from Phase 2 study of trilaciclib in TNBC » 07:28
06/04/23
06/04
07:28
06/04/23
07:28
GTHX

G1 Therapeutics

$2.62 /

+0.09 (+3.56%)

G1 Therapeutics presented…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 07:28

Get Free Trial

ShowHide Related Items >><<
GTHX G1 Therapeutics
$2.62 /

+0.09 (+3.56%)

GTHX G1 Therapeutics
$2.62 /

+0.09 (+3.56%)

01/30/23 JPMorgan
G1 Therapeutics upgraded to Neutral into data catalysts at JPMorgan
01/30/23 JPMorgan
G1 Therapeutics upgraded to Neutral from Underweight at JPMorgan
01/04/23 EF Hutton
G1 Therapeutics initiated with a Buy at EF Hutton
01/03/23 Needham
G1 Therapeutics named as Top Pick, added to Conviction list at Needham
GTHX G1 Therapeutics
$2.62 /

+0.09 (+3.56%)

  • 18
    Nov
GTHX G1 Therapeutics
$2.62 /

+0.09 (+3.56%)

Periodicals
Saudi Arabia, some OPEC members clash over production quotas, WSJ reports » 06:37
06/04/23
06/04
06:37
06/04/23
06:37
BP

BP

$35.64 /

+0.93 (+2.68%)

, COP

ConocoPhillips

$102.36 /

+3.04 (+3.06%)

, SHEL

Shell

$58.25 /

+1.16 (+2.03%)

, TTE

TotalEnergies

$59.20 /

+1.58 (+2.74%)

, XOM

Exxon Mobil

$105.74 /

+2.42 (+2.34%)

, CVX

Chevron

$156.24 /

+4.09 (+2.69%)

Saudi Arabia and some…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:37

Get Free Trial

ShowHide Related Items >><<
XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

SHEL Shell
$58.25 /

+1.16 (+2.03%)

CVX Chevron
$156.24 /

+4.09 (+2.69%)

COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

BP BP
$35.64 /

+0.93 (+2.68%)

BP BP
$35.64 /

+0.93 (+2.68%)

05/04/23 Credit Suisse
BP price target lowered to 610 GBp from 630 GBp at Credit Suisse
05/04/23 Berenberg
BP price target lowered to 560 GBp from 590 GBp at Berenberg
05/03/23 DZ Bank
BP downgraded to Hold from Buy at DZ Bank
05/03/23 AlphaValue/Baader
BP upgraded to Add from Sell at AlphaValue/Baader
COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

05/19/23 Mizuho
ConocoPhillips price target lowered to $126 from $128 at Mizuho
05/18/23 Piper Sandler
ConocoPhillips price target raised to $149 from $140 at Piper Sandler
05/15/23 Morgan Stanley
ConocoPhillips price target raised to $124 from $122 at Morgan Stanley
05/01/23 Goldman Sachs
Exxon Mobil downgraded to Neutral from Buy at Goldman Sachs
SHEL Shell
$58.25 /

+1.16 (+2.03%)

05/24/23 Citi
Citi opens 'downside catalyst watch' on Shell into capital markets day
05/18/23 Piper Sandler
Shell price target lowered to $75 from $77 at Piper Sandler
04/20/23 Piper Sandler
Shell price target raised to $77 from $75 at Piper Sandler
04/19/23 JPMorgan
Shell price target lowered to 2,950 GBp from 3,000 GBp at JPMorgan
TTE TotalEnergies
$59.20 /

+1.58 (+2.74%)

05/19/23 Deutsche Bank
TotalEnergies price target raised to EUR 59.80 from EUR 56.20 at Deutsche Bank
05/18/23 Piper Sandler
TotalEnergies price target lowered to $68 from $69 at Piper Sandler
04/19/23 JPMorgan
TotalEnergies price target lowered to EUR 69 from EUR 73 at JPMorgan
04/11/23 Redburn
TotalEnergies upgraded to Neutral from Sell at Redburn
XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

06/01/23 RBC Capital
Exxon Mobil downgraded to Sector Perform from Outperform at RBC Capital
05/19/23 Mizuho
Exxon Mobil price target lowered to $130 from $147 at Mizuho
05/18/23 Piper Sandler
Exxon Mobil price target raised to $145 from $134 at Piper Sandler
05/15/23 Jefferies
Exxon Mobil price target lowered to $140 from $148 at Jefferies
CVX Chevron
$156.24 /

+4.09 (+2.69%)

06/01/23 RBC Capital
Chevron upgraded to Outperform from Sector Perform at RBC Capital
05/31/23 JPMorgan
Chevron upgraded to Neutral from Underweight at JPMorgan
05/24/23 Mizuho
Chevron price target raised to $202 from $196 at Mizuho
05/24/23 Mizuho
PDC Energy downgraded to Neutral from Buy at Mizuho
XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

TTE TotalEnergies
$59.20 /

+1.58 (+2.74%)

SHEL Shell
$58.25 /

+1.16 (+2.03%)

CVX Chevron
$156.24 /

+4.09 (+2.69%)

COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

BP BP
$35.64 /

+0.93 (+2.68%)

XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

TTE TotalEnergies
$59.20 /

+1.58 (+2.74%)

SHEL Shell
$58.25 /

+1.16 (+2.03%)

CVX Chevron
$156.24 /

+4.09 (+2.69%)

COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

BP BP
$35.64 /

+0.93 (+2.68%)

XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

TTE TotalEnergies
$59.20 /

+1.58 (+2.74%)

SHEL Shell
$58.25 /

+1.16 (+2.03%)

COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

BP BP
$35.64 /

+0.93 (+2.68%)

XOM Exxon Mobil
$105.74 /

+2.42 (+2.34%)

TTE TotalEnergies
$59.20 /

+1.58 (+2.74%)

SHEL Shell
$58.25 /

+1.16 (+2.03%)

CVX Chevron
$156.24 /

+4.09 (+2.69%)

COP ConocoPhillips
$102.36 /

+3.04 (+3.06%)

BP BP
$35.64 /

+0.93 (+2.68%)

Periodicals
Bank stocks too beaten down, JPMorgan among those to buy now, Barron's says » 06:29
06/04/23
06/04
06:29
06/04/23
06:29
JPM

JPMorgan

$140.47 /

+2.9 (+2.11%)

, CFG

Citizens Financial

$27.79 /

+1.41 (+5.34%)

The past three months saw…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:29

Get Free Trial

ShowHide Related Items >><<
JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

05/23/23 Morgan Stanley
JPMorgan price target raised to $160 from $157 at Morgan Stanley
05/15/23 Jefferies
JPMorgan price target lowered to $149 from $152 at Jefferies
05/12/23 Citi
State Street, BNY Mellon hurt most from FDIC proposal, says Citi
05/12/23 Evercore ISI
JPMorgan price target lowered to $151 from $155 at Evercore ISI
CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

04/20/23 RBC Capital
Citizens Financial price target raised to $52 from $48 at RBC Capital
04/20/23 DA Davidson
Citizens Financial price target lowered to $37 from $40 at DA Davidson
04/20/23 Credit Suisse
Citizens Financial price target lowered to $35 from $44 at Credit Suisse
JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

JPM JPMorgan
$140.47 /

+2.9 (+2.11%)

CFG Citizens Financial
$27.79 /

+1.41 (+5.34%)

Periodicals
Ride not over for Eaton stock, Barron's says » 06:25
06/04/23
06/04
06:25
06/04/23
06:25
ETN

Eaton

$186.48 /

+7.435 (+4.15%)

A year ago, the backlog…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:25

Get Free Trial

ShowHide Related Items >><<
ETN Eaton
$186.48 /

+7.435 (+4.15%)

ETN Eaton
$186.48 /

+7.435 (+4.15%)

05/11/23 UBS
Eaton price target raised to $210 from $205 at UBS
05/09/23 Evercore ISI
Eaton price target raised to $221 from $201 at Evercore ISI
05/03/23 Mizuho
Eaton price target raised to $180 from $168 at Mizuho
05/03/23 Barclays
Eaton price target raised to $159 from $145 at Barclays
ETN Eaton
$186.48 /

+7.435 (+4.15%)

ETN Eaton
$186.48 /

+7.435 (+4.15%)

Periodicals
IBM hiding in plain sight, paying big dividend, Barron's says » 06:21
06/04/23
06/04
06:21
06/04/23
06:21
IBM

IBM

$132.37 /

+2.5698 (+1.98%)

IBM is one of the most…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:21

Get Free Trial

ShowHide Related Items >><<
IBM IBM
$132.37 /

+2.5698 (+1.98%)

IBM IBM
$132.37 /

+2.5698 (+1.98%)

05/12/23
DA Davidson tech/software analysts to hold analyst/industry conference call
04/20/23 TD Cowen
SentinelOne fits criteria for strategic interest, says TD Cowen
04/20/23 BMO Capital
IBM price target lowered to $145 from $155 at BMO Capital
04/20/23 Evercore ISI
IBM price target lowered to $140 from $150 at Evercore ISI
IBM IBM
$132.37 /

+2.5698 (+1.98%)

IBM IBM
$132.37 /

+2.5698 (+1.98%)

IBM IBM
$132.37 /

+2.5698 (+1.98%)

IBM IBM
$132.37 /

+2.5698 (+1.98%)

Periodicals
Twitter loses another senior executive in charge of content, safety, WSJ says » 17:46
06/03/23
06/03
17:46
06/03/23
17:46
TWTR

Twitter

$53.71 /

+ (+0.00%)

A second senior executive…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:46

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$53.71 /

+ (+0.00%)

TWTR Twitter
$53.71 /

+ (+0.00%)

05/12/23 Wedbush
New Twitter CEO positive for Tesla shares, says Wedbush
02/03/23 Morgan Stanley
Sprout, Sprinklr pacts minimize impact of Twitter decision, says Morgan Stanley
12/19/22 Wedbush
End of Twitter CEO reign would be 'major positive' for Tesla, says Wedbush
11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
TWTR Twitter
$53.71 /

+ (+0.00%)

TWTR Twitter
$53.71 /

+ (+0.00%)

Hot Stocks
Janssen Pharmaceuticals announces updated data from Phase 2 TRiMM-2 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Janssen presents analysis of infections, parameters in Monumen-TAL1 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Replimune Group announces 3 trial-in-progress abstracts at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

Additional Abstracts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

  • 09
    Dec
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

Hot Stocks
Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

, BMY

Bristol-Myers

$65.66 /

+0.98 (+1.52%)

Replimune Group (REPL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

05/01/23 Barclays
Bristol-Myers price target lowered to $65 from $66 at Barclays
04/28/23 Credit Suisse
Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
04/21/23 BofA
Bristol-Myers price target raised to $85 from $82 at BofA
04/20/23 H.C. Wainwright
Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

  • 09
    Dec
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

Hot Stocks
Replimune presents RP1 data from IGNYTE trial at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

, BMY

Bristol-Myers

$65.66 /

+0.98 (+1.52%)

Replimune (REPL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

05/01/23 Barclays
Bristol-Myers price target lowered to $65 from $66 at Barclays
04/28/23 Credit Suisse
Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
04/21/23 BofA
Bristol-Myers price target raised to $85 from $82 at BofA
04/20/23 H.C. Wainwright
Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

  • 09
    Dec
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

Conference/Events
BTIG healthcare analysts to hold a reception » 17:25
06/03/23
06/03
17:25
06/03/23
17:25

Healthcare Analysts hold…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:25

Get Free Trial

Hot Stocks
Janssen announces results from Phase 1b RedirecTT-1 study » 17:18
06/03/23
06/03
17:18
06/03/23
17:18
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:18

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Evaxion's trial of EVX-01 met its primary endpoints of safety, tolerability » 17:09
06/03/23
06/03
17:09
06/03/23
17:09
EVAX

Evaxion Biotech

$1.48 /

+ (+0.00%)

Evaxion Biotech presented…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:09

Get Free Trial

ShowHide Related Items >><<
EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

03/31/23 Lake Street
Evaxion Biotech price target lowered to $7 from $18 at Lake Street
11/17/22 Oppenheimer
Evaxion Biotech price target lowered to $11 from $16 at Oppenheimer
07/18/22 Oppenheimer
Evaxion Biotech assumed with an Outperform at Oppenheimer
EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

Hot Stocks
Gracell presents long-term follow up data from study evaluating GC012F » 17:07
06/03/23
06/03
17:07
06/03/23
17:07
GRCL

Gracell

$3.05 /

+0.09 (+3.04%)

Gracell Biotechnologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:07

Get Free Trial

ShowHide Related Items >><<
GRCL Gracell
$3.05 /

+0.09 (+3.04%)

GRCL Gracell
$3.05 /

+0.09 (+3.04%)

03/27/23 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
12/08/22 H.C. Wainwright
Gracell initiated with a Buy at H.C. Wainwright
09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
GRCL Gracell
$3.05 /

+0.09 (+3.04%)

Hot Stocks
Sutro Biopharma announces results from Phase 1 dose-expansion study of luvelta » 17:02
06/03/23
06/03
17:02
06/03/23
17:02
STRO

Sutro Biopharma

$4.71 /

+0.255 (+5.72%)

Sutro Biopharma announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:02

Get Free Trial

ShowHide Related Items >><<
STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

04/03/23 JMP Securities
Sutro Biopharma price target lowered to $17 from $20 at JMP Securities
03/31/23 H.C. Wainwright
Sutro Biopharma price target lowered to $16 from $20 at H.C. Wainwright
03/20/23 Wells Fargo
Sutro transferred with Equal Weight from Overweight at Wells Fargo
01/13/23 Truist
Sutro Biopharma price target raised to $25 from $21 at Truist
STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

Hot Stocks
Equitrans Midstream's Mountain Valley Pipeline to proceed » 16:58
06/03/23
06/03
16:58
06/03/23
16:58
ETRN

Equitrans Midstream

$9.08 /

+0.24 (+2.71%)

On June 3, 2023, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:58

Get Free Trial

ShowHide Related Items >><<
ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

06/01/23 Wolfe Research
Equitrans Midstream upgraded to Outperform from Peer Perform at Wolfe Research
05/30/23 RBC Capital
Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital
04/21/23 Raymond James
Equitrans Midstream initiated with a Market Perform at Raymond James
04/10/23 Barclays
Equitrans Midstream price target lowered to $6 from $8 at Barclays
ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

Hot Stocks
Cogent Biosciences announces data from ongoing Phase 3 PEAK trial » 16:56
06/03/23
06/03
16:56
06/03/23
16:56
COGT

Cogent Biosciences

$12.97 /

+0.245 (+1.93%)

Cogent Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:56

Get Free Trial

ShowHide Related Items >><<
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

04/27/23 Baird
Cogent Biosciences initiated with Outperform, $20 target at Baird
04/27/23 Baird
Cogent Biosciences initiated with an Outperform at Baird
04/17/23 Wedbush
Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed
03/27/23 H.C. Wainwright
Cogent Biosciences assumed with a Buy at H.C. Wainwright
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

  • 14
    Jun
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.